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Abstract
Candida infections are a significant source of patient morbidity and mortality. Candida albicans is the most common pathogen
causing Candida infections. Candida auris is a newly described pathogen that is associated with multi-drug-resistant candidiasis
and candidaemia in humans. The antifungal effects of various essential oils and plant compounds have been demonstrated against
human pathogenic fungi. In this study, the effect of cinnamon leaf and bark essential oils (CEOs) was determined against both
C. albicans and C. auris. The disc diffusion (direct and vapour) and broth microdilution method was used to determine antifungal
activity of the EOs against selected strains (C. albicansATCC 10231,C. albicansATCC 2091 andC. aurisNCPF 8971) whilst the
mode of action and haemolysin activity of the CEOs were determined using electron microscopy and light microscopy. Direct and
vapour diffusion assays showed greater inhibitory activity of bark CEO in comparison with leaf CEO. The minimum inhibitory
concentrations (MICs) and minimum fungicidal concentrations (MFCs) of bark CEO for all tested strains was below 0.03% (v/v),
which was lower than the MICs of the leaf CEO (0.06–0.13%, v/v) dependent on the strain and the MFCs at 0.25% (v/v). In the
morphological interference assays, damage to the cell membrane was observed and both CEOs inhibited hyphae formation. The
haemolysin production assay showed that CEOs can reduce the haemolytic activity in the testedC. albicans andC. auris strains. At
low concentrations, CEOs have potent antifungal and antihaemolytic activities in vitro against C. albicans and C. auris.
Key points
• Essential oils from Cinnamomum zeylanicum Blume bark and leaf (CBEO and CLEO) demonstrated fungicidal properties at
very low concentrations.
• The antifungal activity of CBEO was greater than that of CLEO consistent with other recent published literature.
• The mode of action of CBEO and CLEO was damage to the membrane of C. albicans and C. auris.
• Both CBEO and CLEO inhibited the formation of hyphae and reduced haemolysin production in C. albicans and C. auris.
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Introduction
Fungal infections are common diseases of the natural world. In
humans, fungal infections occur when the immune system is
unable to deal with a considerable amount of trespassing fungi
or yeast invading an area of the body. There are several classes
of fungal infections, and of these, Candida infections are
regarded as a significant cause of patient morbidity and mortal-
ity (Sardi et al. 2013). Candida infections are caused by com-
mensal fungi Candida spp., especially Candida albicans,
which resides on the skin, mucosa and gastrointestinal tract of
30 to 50% of healthy adults at any given time, with everyone
being colonized at some point in their lifetime (Brown and
Netea 2007). Candida auris is a newly described opportunistic
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pathogen, which grows as yeast. C. auris is known to be resis-
tant to several classes of antifungal drugs including the first-line
antifungal, fluconazole, and exhibits variable susceptibility to
other azoles, amphotericin B, and echinocandins (Chowdhary
et al. 2016). Additionally,C. auris has a potential for person-to-
person transmission, challenging clinicians and infection con-
trol teams (Ben-Ami et al. 2017).
Essential oils (EOs) are considered plant-originated com-
plex liquid mixtures of volatile and low molecular weight sub-
stances (Amorati et al. 2013; Raut and Karuppayil 2014).
Recently, natural products extracted from traditional medicine
have contributed to the development of innovative modern
drugs (Yunes et al. 2005; Almeida et al. 2001). Antifungal
activity against various plant and human pathogenic fungi in-
cluding yeasts have been discovered in numerous EOs (Raut
and Karuppayil 2014; Chen et al. 2013; Bajpai et al. 2009; Li
et al. 2014). Cinnamomum zeylanicum Blume (a synonym of
Cinnamon verum J. Presl) commonly known as Sri Lanka cin-
namon is widely cultivated in India, China, Sri Lanka, and
Australia (Prasad et al. 2009). The EOs made from its leaf
and bark have been described as having useful antiseptic,
immunostimulant, detoxifying, analgesic and antidepressant ef-
fects (Thosar et al. 2013; Gautam et al. 2014; Vaseeharan and
Thaya 2014; Tworkoski 2002; Topa et al. 2018).
In India, Dalchini (C. zeylanicum Blume bark) is often
soaked in water and used as mouthwash solution to treat
dental caries pathogens. The study of Aneja et al. (2009)
showed that Dalchini extract exhibits even much higher anti-
fungal activity than the standard antifungal drug
amphotericin-B on oral pathogens including Saccharomyces
cerevisiae and C. albicans. In addition, the extraction of cin-
namon leaf and bark demonstrated inhibitory activity against
Fusarium graminearum, F. proliferatum, Aspergillus
fumigatus and Trichophyton rubrum in previous studies
(Velluti et al. 2003; Velluti et al. 2004; Khan and Ahmad
2011). In the study by Carvalho et al. (2018), CEOs extracted
from C. zeylanicum were shown to inhibit some virulence
factors in clinical strains of C. albicans such as proteinase
production, germ tube formation and adhesion to buccal epi-
thelial cells. Moreover, previous studies have reported that
cinnamaldehyde and eugenol, which are the main components
of bark and leaf cinnamon essential oils, respectively, have
demonstrated active in vitro tested against dermatophyte
strains isolated from patients with dermatophytosis inhibiting
80% of the dermatophyte strains tested (Gruenwald et al.
2010). However, to our knowledge, there is little data avail-
able demonstrating the possibility of utilizing CEOs to treat
infections caused by C. albicans and no evidence to date of
EO activity against C. auris.
The focus of this study was to investigate the antifungal
activities and the antihaemolytic effects of the oils extracted
from leaf and bark of C. zeylanicum Blume against
C. albicans and C. auris.
Methods
Fungal organisms
Three organisms were used in this study which included two
strains of C. albicans: ATCC 10231 and ATCC 2091 and one
strain of C. auris: NCPF 8971. The C. albicans strains were
provided by the Southmead Hospital, Bristol, UK while the
C. auris was purchased from the National Collection of
Pathogenic Fungi (NCPF) operated by Public Health England
(UK). The organisms were maintained on Sabouraud Dextrose
agar (SDA, CM0041, Oxoid Ltd., UK) at 30 and 4 °C until
used in tests. The inoculum was prepared from C. albicans and
C. auris cultures, plated on SDA and incubated at 30 °C for
48 h and prior to each experiment, was standardized using 0.5
McFarland with a final concentration at approximately 106
colony-forming units per millilitre (CFU/mL).
Essential oils used in this study
The bark CEO (Cinnamomum zeylanicum Blume; CBEO)
was donated by Amphora Aromatics Ltd., UK for research
purposes and the leaf CEO (Cinnamomum zeylanicum
Blume; CLEO) was purchased from Freshskin Beauty Ltd.,
UK. The EOs were kept at room temperature throughout the
experimental period.
Gas chromatography mass spectroscopy
Using similar methods to Zeng et al. (2015), gas chromatog-
raphy mass spectroscopy (GC-MS) analysis was performed
using the Agilent 6890 N Gas Chromatograph system
(Agilent Technologies, USA) to identify the component pro-
files in the tested oils. Data acquisition and analysis was per-
formed using the Agilent MassHunter software (Agilent
Technologies, USA) based on the retention times and mass
spectra.
Antifungal susceptibility testing using the disc
diffusion assay
Direct contact
The agar disc diffusion method described by Adukwu et al.
(2016) was used for determination of the antifungal properties
of CEOs. Miconazole (Sigma, USA) with the concentration at
10 μg/mL dissolved in DMSO (Sigma) was used as the refer-
ence antifungal drug. Briefly, 100 μL of yeast suspension was
spread onto SDA plates and then paper discs (6 mm, Sigma)
impregnated with 10 μL of essential oils or dissolved micon-
azole were placed over the agar surface, and plates were incu-
bated at 30 °C for 48 h. Plates with discs in the absence of any
treatment were used as reference controls. The diameter of the
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resulting inhibition zone in the fungal lawn was measured in
millimetres.
Disc volatilisation assay
The antifungal activity of CEOs in vapour phase was investi-
gated using the disc volatilisation technique (Boukhatem et al.
2014). Briefly, 100 μL of yeast suspension was spread onto
SDA plates and then paper discs (6 mm, Sigma) impregnated
with 10 μL of essential oils or dissolved miconazole were
placed on the inside surface of the upper lid. The plate was
sealed with parafilm to prevent leakage of the vapour and was
promptly inverted on top of the lid. Plates were incubated at
30 °C for 48 h, and the diameter of the zone of inhibition was
recorded in millimetres.
Determination of minimum inhibitory concentration
and minimum fungicidal concentration using broth
dilution method
The method used in this study for determination of minimum
inhibitory concentration (MIC) and minimum fungicidal con-
centration (MFC) of CEOs was adapted from Adukwu et al.
(2012) with slight modifications. Briefly, Sabouraud Dextrose
broth (SDB, Oxoid Ltd., UK) was prepared with a 0.5% (v/v)
concentration of Tween 20 (Sigma, USA), used as the EO
emulsifier. Both CBEO and CLEO were diluted twofold into
SDBwith Tween 20 to create a concentration range between 4
and 0.03% (v/v). The amount of 180 μL of the diluted CEOs
was transferred into the corresponding wells of a 96-well
microdilution plate with 20 μL of yeast suspension.
Microplate wells of EO dilutions without yeast, and SDB
and yeast suspension, were used as negative controls, and
the plates incubated at 30 °C for 48 h. After the appropriate
incubation time, the optical density (OD) of each well was
recorded at 595 nm using the microplate reader
(infinteF200Pro, Tecan, Switzerland). The MIC was defined
as the lowest CEO concentration that produced inhibition of
yeast growth.
MFC was measured by transferring 20 μL from each treat-
ed well of CEO concentration from 4% (v/v) to 0.03% (v/v) to
labelled SDA plates followed by incubation at 30 °C for 48 h.
The MFC was defined as the lowest CEO concentration that
inhibited growth of the yeast or permitted less than three
CFUs to occur, resulting thus in 99.9% fungicidal activity
(Espinel-Ingroff et al. 2002).
Effect of CEOs on the micromorphology of C. albicans
and C. auris
To investigate changes in morphology caused by expo-
sure to the CEOs against C. albicans and C. auris, we
adapted the methods of Leite et al. (2014) with some
modofications. One hundred microlitres (100 μL) of
yeast suspension was spread onto cornmeal agar plates
and then paper discs (6 mm, Sigma) were impregnated
with 10 μL of essential oils and placed over the agar
surface and the plates incubated at 30 °C for 48 h. Agar
plates with discs without any treatments were used as
reference controls. Plates were then visualised using the
light microscope (Olympus, UK), tenfold magnification.
Following incubation, two to three fungal colonies at
the edge of the inhibitory zone were gently removed
and placed on a clean microscope slide. A drop of
Lacto-Fuchsin stain was placed on the sample and cov-
ered by a coverslip. The slides were examined under
light microscope with 40-fold magnification.
Modulation of cell membrane permeability
To assess the integrity of the yeast cell membranes following
treatment with the CEO exposure, the cellular content leakage
assay method described by Khan et al. (2013) was adapted
with some modifications. Briefly, 200 μL of cell suspensions
were transferred to wells of the 24-well plates (SLS, UK)
containing 1800 μL of diluted CEOs at different concentra-
tions (0.03, 0.015 and 0.008% (v/v) for CBEO; 0.13, 0.06 and
0.03% (v/v) for CLEO). CEOs in PBS served as blank, un-
treated cells in PBS as controls. Plates were incubated at 30 °C
for 24 h. After the incubation period, the samples were centri-
fuged (1250 rpm, 2 min) and the release of cellular material in
the supernatants was determined by using spectrophotometric
measurement of cell supernatant at 260/280 nm (correspond-
ing to nucleic acids and proteins).
Scanning electron microscopy
Three sets of samples of the test strains were prepared
with treatments at 0.03 and 0.015% (v/v) for CBEO and
0.13 and 0.06% (v/v) for CLEO. Control samples which
consisted of the organisms without any treatment were
also prepared. Fungal cultures were grown for 48 h in
SDB, and 100 μL of the samples were dropped onto
sterile metal discs and incubated for 48 h at 30 °C to
establish fungal growth. The samples were then fixed
using glutaraldehyde fixative. Periodic hourly rinsing
of the samples three times with PBS was required to
minimize any activity of the CEOs and to allow for
clearing of any debris, which could affect the viewing
of the samples. After that, samples were dehydrated
using ethanol at different concentrations from 20 to
100% (v/v) and hexamethyldisilazane. Samples were
then air dried, gold coated and visualized using the
FEI Quanta FEG 650 SEM (Thermo Fisher Scientific,
USA).
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Assessment of Haemolytic activity
Haemolytic activities of Candida strains and CEOs
To determine haemolytic activity of the Candida isolates,
SDA medium containing 7% (v/v) horse blood (TCS
Biosciences Ltd. UK) with or without 3% (w/v) glucose was
used. A 10-μL yeast suspension or diluted CEOs at different
concentrations from 4% (v/v) to 0.03% (v/v) was inoculated
onto plates in triplicate; these were then incubated at 37 °C for
24 h in aerobic condition. After incubation, a transparent/
semi-transparent zone around the inoculation site was consid-
ered positive haemolytic activity. The ratio of the diameter of
the colony to that of the translucent zone of haemolysis (mm)
was used as the haemolytic index, as described by Wan et al.
(2015).
Effect of CEOs on the haemolytic activity of Candida isolates
The inhibition of haemolysin production in tested strains was
conducted using the method of Manns et al. (1994) with some
modifications. Briefly, Candida isolates were grown in SDB
with 8% (v/v) glucose and CBEO at final concentrations of
0.03, 0.015 and 0.008% (v/v) and CLEO at final concentra-
tions of 0.13, 0.06 and 0.03% (v/v) and incubated at 37 °C for
48 h. The SDB without CEOs was used as a control. The
supernatant was collected from the incubated broth cultures
by centrifuging at 5000 rpm for 30min. Freshly washed sterile
RBCs from horse blood (TCS Biosciences Ltd. UK)
suspended in sterile PBS and enriched with 5% (w/v) glucose
were mixed in a ratio of 1:1 with the supernatant and incubat-
ed at 37 °C for 3 h. Tubes were centrifuged at 2000 rpm for
10 min and read at 540 nm. Mean absorbance values were
used to calculate the reduction percentage in the production
of haemolysin in treated samples over untreated controls.
Results
Analysis of chemical composition (GC-MS)
The qualitative and quantitative composition of the used
CBEO and CLEO is shown in Table 1. The number of
identified components was greater in CLEO representing
approximately 93% of the entire EO than the CBEO
representing approximately 95%. The CLEO was char-
acterized by high amounts of eugenol at 62.57% whilst
in the CBEO this component was only 5.28%. The
main component of CBEO was trans-cinnamaldehyde
(66.43%) with <2% of this compound identified in the
CLEO.
Antifungal susceptibility screening
Results from the antifungal susceptibility tests are summa-
rized in Table 2. Both CBEO and CLEO demonstrated stron-
ger antifungal activity against tested strains when compared
with miconazole—an antifungal drug that is typically used in
treatment of skin infections including those caused by yeast,
e.g. candidiasis. The CBEO demonstrated greater inhibitory
activity against C. albicans and C. auris in comparison with
CLEO in the direct disk diffusion and disk volatilisation as-
says (Table 2). The CBEO was approximately twice as effec-
tive as the CLEO (direct contact) and approximately between
2 to 3.5 times more effective than CLEO (vapour assay).
Inhibitory and fungicidal activity
Results in Table 3 showed that C. albicans and C. auris were
susceptible to CBEO and CLEO at low concentrations with
both yeast species exhibiting greater susceptibility to CBEO
withMIC andMFC activity observed at concentrations below
0.03% (v/v). The inhibitory action of CLEO against the
Candida spp. at low concentrations between 0.06 and 0.13%
(v/v) was effective at inhibiting the growth of C. albicans and
C. auris strains; however, fungicidal activity of CLEO was
observed at 0.25% (v/v).
Effect of CEOs on the micromorphology of C. albicans
and C. auris
Results from the cornmeal agar assay showed that the
C. albicans strains were predominantly comprised of filaments
and after exposure to the EOs, hyphae formation was notice-
ably reduced in both C. albicans strains, especially C. albicans
ATCC 2091. No change in morphology in the C. auris isolate
was observed before and after exposure to both CEOs.
Actions of CEOs on cell membrane permeability
The mechanism of action of CBEO and CLEO on C. albicans
and C. auriswas determined by cellular content leakage assay
and scanning electronmicroscopy (SEM)morphological anal-
ysis following treatment with both CBEO and CLEO. The
cellular content leakage assay shows that the envelop of the
Candida spp. under investigation was damaged by the CEOs,
demonstrated by the nucleic acid and protein release, i.e. cell
lysis (Figs. 1 and 2). These results were supported by SEM
images, which revealed receding of the cell membrane and
shrinkage of cell surfaces (Fig. 3).
In the cell content leakage assay, an increase in OD260 nm
indicates a release of nucleic acid whilst the OD280 nm shows
protein release. Following exposure of the test organisms to
CBEO, nucleic acid and protein release were observed
(p < 0.05). In addition, the higher the concentration, the
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greater the nucleic acid and protein leakage. Figure 2 also
demonstrates cell content leakage following exposure to
CLEO at the MIC and concentrations below the MIC; how-
ever, the cell content leakage was not significantly different
(p > 0.05) from the untreated samples at 0.06 and 0.03% (v/v).
The MIC and MFC of CBEO were found to be below the
test concentration range < 0.03% (v/v) and at 0.015% (v/v); the
three test organisms were damaged and had lost turgidity and
integrity when exposed to these concentrations (observed by
SEM).C. albicansATCC 2091 andC. aurisNCPF 8971were
killed at 0.13% (v/v) of CLEOwhile the control cells appeared
turgid and whole with smooth cell membrane (Fig. 3a–c).
Figure 3 (m-o) shows some undamaged cells when the cells
were exposed to CLEO at 0.06% (v/v; MIC for C. albicans
ATCC 2091 and C. auris NCPF 8971) which is a confirma-
tion of fungistatic activity at that concentration and at 0.13%
(v/v), the cells were damaged by the CLEO.
Haemolysin activities of Candida isolates
In the glucose-enriched agar plates, two different types of
haemolysis were observed circumscribing the yeast “colony”
when viewed with transmitted light. The first was a totally
translucent ring identical to beta-haemolysis, and the second
was a greenish-black halo comparable with alpha-haemolysis.
At 24 h incubation, only alpha-haemolysis was observed in
the glucose-free plates. However, after 48 h incubation, only
beta-rings were observed in glucose-free plates. We clearly
observed greater haemolytic activity in the three tested strains
in the glucose-enriched plates compared with the glucose-free
plates.
Results in Table 4 show the haemolysin activities of
Candida isolates. In both glucose-enriched and glucose-free
plates, haemolysis activity was higher in C. albicans ATCC
10231 with the mean diameters of alpha- and beta-rings in
Table 1 GC-MS analysis of
CBEO and CLEO showing major
components
Components Cinnamon leaf (%) Cinnamon bark (%)
Bicyclo [3.1.1] hept-2-ene, 3,6,6-trimethyl- 2.54 –
Alpha-Phellandrene 2.27 –
Benzene, 1-methyl-4-(1-methylethyl)- 1.7 –
Cyclohexene, 1-methyl-5-(1-methylethenyl)-, (R)- 1.43 –
1,6-Octadien-3-ol, 3,7-dimethyl- 3.79 7.61
Eugenol 62.57 5.28
Caryophyllene 4.17 –
Benzyl benzoate 4.09 2.86
Phenol, 2-methoxy-4-(2-propenyl)-, acetate 3.49 –
trans-Cinnamaldehyde 1.92 66.43
1,3-Benzodioxole, 5-(2-propenyl)- 1.73 –
2-Propen-1-ol, 3-phenyl-, acetate 2.3 –
Eucalyptol 0.33 6.63
Butane, 2-methyl- – 4.74
Benzaldehyde 0.27 1.04
Percentage of total components in the EO 92.6 94.59
Table 2 Inhibitory zones (mm) of fungal growth in C. albicans and C. auris by bark CEO, leaf CEO and miconazole (10 μg/mL) after 48 h of
incubation
Selected yeasts Mode of exposure or treatment Bark CEO Leaf CEO Miconazole
Mean (mm) SE Mean (mm) SE Mean (mm) SE
C. albicans ATCC 10231 53.00 1.68 26.32 0.67 24.33 1.37
C. albicans ATCC 2091 Direct contact 56.68 0.85 30.17 0.76 31.33 0.97
C. auris NCPF 8971 70.40 1.53 39.67 1.00 32.82 0.39
C. albicans ATCC 10231 55.52 0.65 15.08 0.82 NA NA
C. albicans ATCC 2091 Vapour exposure 59.72 1.07 18.90 0.33 NA NA
C. auris NCPF 8971 77.37 1.72 35.40 1.08 NA NA
Results were from three independent experiments performed in triplicate (N = 3)
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glucose-enriched plates after 24 h incubation being 15.51 ±
0.36 and 21.46 ± 0.6 mm, respectively. Meanwhile, in the
glucose-free agar plates, the mean diameter of alpha-rings of
C. albicans ATCC 10231 was 11.42 ± 0.31 mm. After 48 h
incubation, the mean diameters of alpha- and beta-rings of
C. albicans ATCC 10231 in glucose-added plates were still
the highest among three tested stains. The mean diameter of
beta-rings of C. albicans ATCC 10231 in glucose-free plates
was 16.63 ± 0.41 mm. In contrast, haemolysis was lower in
C. auris NCPF 8971 with mean alpha- and beta-rings in
glucose-enriched plates after 24 h incubation were 10.61 ±
0.4 and 16.43 ± 0.43 mm, respectively. After 48 h incubation,
the mean diameter of beta-rings of C. auris NCPF 8971 in
glucose-free plates was 14.56 ± 0.23 mm.
Effects of bark and leaf CEOs on the haemolytic
activity of C. albicans and C. auris
An antifungal agent may either increase or attenuate the viru-
lence factors released by fungal cells (Khan and Ahmad,
2013). Clinical performance of an antifungal compound is
not only determined by its fungicidal or fungistatic activity
but also by its influence on virulence factor release (Lopes
et al. 2013). To ensure that the CEO concentration in this test
was not directly responsible for the haemolytic activity fol-
lowing the challenge with the yeast species under investiga-
tion, assays to test the haemolysis activity of CBEO and
CLEO were conducted on horse blood agar (Fig. 4). The re-
sults indicated that both CEOs could cause haemolytic activity
at high concentration; however, at concentrations ≤1% (v/v)
for CBEO and < 0.5% (v/v) for CLEO, both CEOs did not
cause any haemolytic activity in vitro.
The results from the inhibitory effects of CBEO and CLEO
on the haemolytic activity of C. albicans and C. auris are
presented in Fig. 5. Following treatment with both CEOs at
different concentrations, haemolytic activity was reduced in
all tested organisms. CBEO at 0.03% (v/v) and 0.015% (v/v)
reduced haemolysis in the tested strains to lower than 20%
overall and at 0.008% (v/v) haemolysis was reduced by ap-
proximately 30% (Fig. 5a). At the same concentration,
haemolysis was reduced by over 80%. CLEO also reduced
haemolytic activity of C. albicans and C. auris at the MIC
and the concentration 2× MIC (Fig. 5b). At the sub-inhibitory
concentration, 0.5× MIC, there was no significant difference
between the treated and untreated strain (C. albicans ATCC
10231; p > 0.05).
Discussion
Analysis of chemical composition (GC-MS)
The GC-MS results in this study were similar to that of
Mayaud et al. (2008) with the exception of cinnamaldehyde,
which was not found in the CLEO, analysed in their paper.
Previous studies have shown that both trans-cinnamaldehyde
and eugenol, the key components of CBEO and CLEO, re-
spectively have been are antimicrobial against bacteria and
fungi. In a recent review article by Doyle and Stephens
(2019), trans-cinnamaldehyde was found to be responsible
for causing damage to the bacterial cells via different methods;
cell release activity, anti-quorum sensing activity, effect on
ATP etc. Eugenol, on the other hand, has been shown to cause
morphological changes and damage to Candida albicans-ad-
herent cells and biofilms (He et al. 2007). To our knowledge,
very little is known on the effects of EOs against the new
pathogen C. auris and there are no published reports on the
effects of CEOs against this pathogen.
Antifungal activity of CBEO and CLEO
The susceptibility ofC. albicans and C. auris to the antifungal
effects of bark and leaf CEO when in contact with the fungal
lawns and in vapour phase was determined. The results were
consistent with the studies by Brnawi et al. (2018) and
Ranasinghe et al. (2002) who found CBEO to be a more
effective antimicrobial than CLEO. Research into the antimi-
crobial vapour investigations using EOs is gaining interest,
and our results further support this with CBEO demonstrating
strong antimicrobial activity in vapour phase while CLEO
produces major inhibition in direct contact. The main compo-
nent of CBEO is trans-cinnamaldehyde and that of CLEO is
eugenol. The study by Sanla-Ead et al. (2012) investigated the
antifungal activity of trans-cinnamaldehyde and eugenol and
Table 3 The antifungal activity
of bark and leaf CEO (MICs and
MFCs) against C. albicans and
C. auris
Selected yeasts Bark CEO Leaf CEO
MIC % (v/v) MFC % (v/v) MIC % (v/v) MFC % (v/v)
C. albicans ATCC 10231 < 0.03 < 0.03 0.13 0.25
C. albicans ATCC 2091 < 0.03 < 0.03 0.06 0.25
C. auris NCPF 8971 < 0.03 < 0.03 0.06 0.25
Results were from three independent experiments performed in triplicate (N = 3)
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found that trans-cinnamaldehyde displayed stronger antifun-
gal activity in vapour phase which might explain why CBEO
was more effective in vapour phase when compared with
CLEO. Antimicrobial activity via vapour diffusion offers a










































Bark CEO 0.008 %
Fig. 1 Assessment of (a) nucleic acid release, OD260 nm and (b) protein
release OD280 nm from C. albicans and C. auris after treatment with
cinnamon bark essential oil at 0.008, 0.015 and 0.03% (v/v). This
experiment was carried out on three separate occasions (N = 3) with the
bars showing mean values (± SE)
8917Appl Microbiol Biotechnol (2020) 104:8911–8924
different delivery mode for the CEOs and other essential oils
for the treatment andmanagement of infections, e.g. in clinical
settings to improve air quality by means of decontamination.
Both CBEO and CLEO demonstrated fungicidal properties
at very low concentrations. C. auris has been described as a
notorious nosocomial pathogen requiring urgent efforts to un-
derstand and to identify therapeutic options due to high trans-
missibility, challenges with identification, incorrect use of an-
tifungal drugs and treatment failures, which lead to high mor-
tality (Sears and Schwartz 2017; Sardi et al. 2018). The
(a)
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Leaf CEO 0.03 %
Fig. 2 Assessment of (a) nucleic acid release, OD260 nm and (b) protein
release OD280 nm from C. albicans and C. auris after treatment with
cinnamon leaf essential oil at 0.03, 0.06 and 0.13% (v/v). This
experiment was carried out on three separate occasions (N = 3) with the
bars showing mean values (± SE)
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Column 1: SEM of 
C. albicans ATCC 10231 
Column 2: SEM of  
C. albicans ATCC 2091 
Column 3: SEM of 
C. auris NCPF 8971 
a b c 
d e f 
g h i 
j k l 
m n o 
Fig. 3 Scanning electron microphotographs of C. albicans ATCC 10231
(column 1),C. albicansATCC 2091 (column 2) andC. aurisNCPF 8971
(column 3). (a–c) Untreated cells; (d–f) Bark CEO 0.03% (v/v) treated
cells; (g–i) Bark CEO 0.015% (v/v) treated cells; (j–l) leaf CEO 0.13% (v/
v treated cells; (m–o) The white arrows indicate fungal cells which are
undamaged or having a minor damage under treatments. Magnification, ×
5000
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limited antifungal treatment options for this important patho-
gen creates a need to develop new alternative treatments in
line with the global antimicrobial resistance strategies, which
indicates the development of new treatments and reduce reli-
ance on existing conventional antimicrobials as an important
step.
Fig. 4 Photographs depicting the
hemolysis of horse blood agar
(supplemented with 3% w/v of
glucose) induced by different
concentrations of bark CEO (1, 2)
and leaf CEO (3, 4). Panel a
shows pure bark CEO (a) and
pure leaf CEO (k) served as posi-
tive control; Sabouraud dextrose
broth +0.5% Tween 20 served as
negative control (j); bark CEO 4%
(b); bark CEO 2% (c); bark CEO
1% (d); bark CEO 0.5% (e); bark
CEO 0.25% (f); bark CEO
0.125% (g); bark CEO 0.06% (h);
bark 0.03% (i); leaf CEO 4% (l);
leaf CEO 2% (m); leaf CEO 1%
(n); leaf CEO 0.5% (o); leaf CEO
0.25% (p); leaf CEO 0.125% (q);
leaf CEO 0.06% (r); and leaf CEO
0.03% (s)
Table 4 Diameters ofα- andβ-rings (mm) representing haemolytic activity ofC. albicansATCC 10231,C. albicansATCC 2091 and C. aurisNCPF
8971 with and without glucose enrichment after incubation for 24 and 48 h
Organisms Glucose conc. (w/v) Incubation time (h) α-Ring (mm) β-Ring (mm)
Candida albicans ATCC 10231 3 24 15.51 (± 0.36) 21.46 (± 0.60)
0 11.42 (± 0.31) 0 (non-haemolytic)
3 48 17.72 (± 0.15) 28.83 (± 0.46)
0 0 (non-haemolytic) 16.63 (± 0.41)
Candida albicans ATCC 2091 3 24 14.26 (± 0.33) 20.7 (± 0.43)
0 10.96 (± 0.27) 0 (non-haemolytic)
3 48 17.7 (± 0.35) 26.2 (± 0.75)
0 0 (non-haemolytic) 16.38 (± 0.37)
Candida auris NCPF 8971 3 24 10.61 (± 0.40) 16.43 (± 0.43)
0 9.7 (± 0.16) 0 (non-haemolytic)
3 48 15.11 (± 0.36) 24.54 (± 0.43)
0 0 (non-haemolytic) 14.56 (± 0.23)
Results were from three independent experiments performed in triplicate (N = 3)
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Effect of CEOs on the micromorphology of C. albicans
and C. auris
Germination is considered one of the major virulence factors
known to contribute to Candida pathogenesis (Larkin et al.
2017). In C. albicans, virulence gene expression is linked to
its ability to transition from yeast form to hyphal form (Gow
et al. 2002). The yeast-to-hyphal transition in C. albicans is
known to promote virulence because hyphae can exert me-
chanical force to breach and damage endothelial cells
(Thompson et al. 2011). Moreover, macrophages and neutro-
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Fig. 5 Effects of CBEO (a) and CLEO (b) at different concentrations on
the inhibition of haemolysis in C. albicans ATCC 10231; C. albicans
ATCC 2091 and C. auris NCPF 8971. This experiment was carried out
on three separate occasions and in triplicate (N = 3) with the bars showing
mean values (± SE)
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et al. 1997). In the presence of CEOs, hyphal formation was
inhibited in the C. albicans strain ATCC 2091, suggesting a
potential mechanism of action of the EO as hyphae formation
is associated with release of virulence factors. The findings
also showed that under similar test conditions, C. auris NCPF
8971 did not germinate, form hyphae or produce chlamydo-
spores. Since the ability ofCandida to invade endothelial cells
is important in causing candidemia and candidiasis, the inabil-
ity to form hyphae of C. auris NCPF 8971 suggests that vir-
ulence as described in other studies is likely as a result of other
factors and requires further investigation.
Actions of CEOs on cell membrane permeability
The mechanism of action of CBEO and CLEO on
C. albicans and C. auris was damage to the envelop, evi-
dent by the shrinkage of the cell surfaces and receding of
cytoplasm leading to lysis of cells. In addition, the level of
membrane damages of Candida cells correlated with the
concentration of CEOs used. This finding suggests that the
membrane-destructive action of both CBEO and CLEO
depends on the concentration of oils. This conclusion was
re-confirmed by the increase in the level of nucleotide and
protein in the extracellular media. Khan et al. (2013) pro-
posed that membranous structures such as cell wall and cell
membrane of fungal cells are the target sites of trans-
cinnamaldehyde and eugenol. This activity, in part, can
be due to lipophilic properties of these compounds for their
partition into the lipid bilayer of the plasma membrane
(Knobloch et al. 1989), leading to the disruption of the
structure of different membrane layers and subsequently
permeability. Another study by Shahina et al. (2018) using
utilizing atomic force microscopy (AFM) imaging, laser
scanning confocal Microscopy (LSCM) imaging and
Congo red staining techniques, demonstrated cell surface
exfoliation, altered ultrastructure, delayed cell cycle and
reduced cell wall integrity in C. albicans cells following
exposure to CBEO. In their study, the findings suggested
that not only cinnamaldehyde possess the ability to com-
promise cell membrane and wall integrity but also minor
components of CBEO such as limonene, eugenyl acetate,
linalool and benzyl benzoate contribute to CBEO antifun-
gal activity by other routes of impact such as introducing
spindle defect or arresting cell cycle in the anaphase.
Further assays are needed to determine other sites of action
of the CEOs on Candida spp., e.g. transmission electron
microscopy, sorbitol protection assay or flowcytometry.
However, the results from this study clearly demonstrate
antifungal activity of both CBEO and CLEO against the
C. albicans and for the first time, against C. auris. Both
species of Candida irrespective of morphology switching
action had significantly damaged cell membrane structures
when exposed to low concentrations of the EOs.
Antihaemolytic effect of CEOs
To date, very few studies have investigated the haemolytic
activity of C. auris although it has been shown to be a great
source of nosocomial bloodstream infections (Sardi et al.
2018). Haemolytic activity has been demonstrated in several
studies and is a factor in the pathogenesis of C. albicans (Luo
et al. 2001; Favero et al. 2014). In our study, both C. albicans
and C. auris produced haemolysis in the glucose-enriched
blood media, which is of importance as haemolysis activity
in the presence of glucose has been indicated as a possible
factor in the pathogenesis of Candida in diabetic patients
(Malcok et al. 2009). However, with the presence of CEOs,
at MIC and sub-MICs, both CBEO and CLEO inhibited pro-
duction of haemolysin factors in C. albicans and C. auris
which offers some insight into a not well-described activity
of EOs on Candida spp. supporting our initial findings from
the cornmeal agar assay where switching to hyphal form was
inhibited in the presence of the CEOs. In the review article by
Nayak et al. (2013), there is enhanced haemolytic activity in
C. albicans which is characterized by iron uptake leading to
and secretion of haemolysin, facilitating hyphal invasion dur-
ing candidiasis infections. Thus, the reduction of haemolytic
activity, the prevention of morphology switching from spore
to hyphae and damage to the membrane are demonstrated here
as some of the mechanisms of action of the cinnamon EOs
against the Candida species. The potential of cinnamon EO as
an antifungal agent is also evident with the inhibitory and
fungicidal action against C. albicans and C. auris at low con-
centrations of both leaf and bark oils. Both EOs were shown to
be fast-acting antimicrobials against Pseudomonas
aeruginosa in a recent study by Elcocks et al. (2020), and with
such promising action against two troublesome pathogenic
Candida species, there is a clear need to explore this EO
further as a treatment option for candidiasis infections.
In summary, the findings reported here demonstrate for the
first time the potential of both bark and leaf CEOs to exert
antifungal activity against C. auris, which is a newly found
Candida spp., along with C. albicans. Mode of action of these
oils towards fungal cells determined by SEM analysis, high-
light their ability to damage the membranous structures of
fungal cells. In this study, test Candida strains and CEOs at
high concentrations all showed haemolytic activities. At MIC
and sub-MICs, both bark and leaf CEOs reduced the germi-
nation and haemolysin factors in C. albicans and C. auris.
Further in vivo studies are needed to assess any potentially
toxic effect of CEOs; however, the antifungal and anti-
haemolytic activity raise another interesting field in
researching antifungal therapeutic interventions in both clini-
cal and industrial applications.
Acknowledgements The authors would like to thank Dr. David Patton
and Mr. Paul Bowdler from the Centre for Research in Bioscience
8922 Appl Microbiol Biotechnol (2020) 104:8911–8924
laboratories at UWE Bristol for technical support with Scanning Electron
Microscopy and GC-MS analysis.
Authors’ contributions Hoang N. H. Tran: contribution: conducted lab-
oratory experiments and involved in writing process; roles: conceptuali-
sation, investigation, data curation, visualization and writing—original
draft. Lee Graham: contribution: contributed to research design, critique
and writing; roles: methodology, writing—review and editing.
Emmanuel C. Adukwu: contribution: designed and supervised the re-
search and involved in writing and evaluation of data; roles: conceptual-
ization, supervision, visualization and writing—review and editing.
Data availability Not applicable.
Compliance with ethical standards
Conflict of interest The authors declare that they have no conflict of
interest.
Ethics approval and consent to participate Not applicable.
Consent for publication Not applicable.
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing, adap-
tation, distribution and reproduction in any medium or format, as long as
you give appropriate credit to the original author(s) and the source, pro-
vide a link to the Creative Commons licence, and indicate if changes were
made. The images or other third party material in this article are included
in the article's Creative Commons licence, unless indicated otherwise in a
credit line to the material. If material is not included in the article's
Creative Commons licence and your intended use is not permitted by
statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this
licence, visit http://creativecommons.org/licenses/by/4.0/.
References
Adukwu EC, Allen SC, Phillips CA (2012) The anti-biofilm activity of
lemongrass (Cymbopogon flexuosus) and grapefruit (Citrus
paradisi) essential oils against five strains of Staphylococcus aureus.
J Appl Microbiol 113:1217–1227. https://doi.org/10.1111/j.1365-
2672.2012.05418.x
Adukwu EC, Bowles M, Edwards-Jones V, Bone H (2016)
Antimicrobial activity, cytotoxicity and chemical analysis of lemon-
grass essential oil (Cymbopogon flexuosus) and pure citral. Appl
Microbiol Biotechnol 100:9619–9627. https://doi.org/10.1007/
s00253-016-7807-y
Almeida R, Navarro D, Barbosa-Filho J (2001) Plants with central anal-
gesic activity. Phytomed 8:310–322. https://doi.org/10.1078/0944-
7113-00050
Amorati R, Foti MC, Valgimigli L (2013) Antioxidant activity of essen-
tial oils. J Agric Food Chem 61:10835–10847. https://doi.org/10.
1021/jf403496k
Aneja KR, Joshi R, Sharma C (2009) Antimicrobial activity of Dalchini
(Cinnamomum zeylanicum bark) extracts on some dental caries
pathogens. J Pharm Res 2:1387–1390
Bajpai VK, Jung IY, Sun CK (2009) Antifungal potential of essential oil
and various organic extracts of Nandina domestica Thunb. Against
skin infectious fungal pathogens. Appl Microbiol Biotechnol 83:
1127–1133. https://doi.org/10.1007/s00253-009-2017-5
Ben-Ami R, Berman J, Novikov A, Bash E, Shachor-Meyouhas Y, Zakin
S, Maor Y, Tarabia J, Schechner V, Adler A, Finn T (2017)
Multidrug-resistant Candida haemulonii and C. auris, Tel Aviv,
Israel. Emerg Infect Dis 23:195–203. https://doi.org/10.3201/
eid2302.161486
BoukhatemMN, Ferhat MA, Kameli A, Saidi F, Kebir HT (2014) Lemon
grass (Cymbopogon citratus) essential oil as a potent anti-
inflammatory and antifungal drugs. Libyan J Med 9:25431. https://
doi.org/10.3402/ljm.v9.25431
Brnawi WI, Hettiarachchy NS, Horax R, Kumar-Phillips G, Seo HS,
Marcy J (2018) Comparison of cinnamon essential oils from leaf
and bark with respect to antimicrobial activity and sensory accept-
ability in strawberry shake. J Food Sci 83:475–480. https://doi.org/
10.1111/1750-3841.14041
Brown GD, Netea MG (2007) Immunology of fungal infections.
Springer, Dordrecht. https://doi.org/10.1007/1-4020-5492-0
Chen Y, Zeng H, Tian J, Ban X, Ma B, Wang Y (2013) Antifungal
mechanism of essential oil from Anethum graveolens seeds against
Candida albicans. J Med Microbiol 62:1175–1183. https://doi.org/
10.1099/jmm.0.055467-0
Carvalho PCL, Sá NP, Lacerda ICA, Pataro C, Rosa LH, Alves RS, Lyon
JP, Rosa CA, Johann S (2018) Anti-candida activity of cinnamon
inhibition of virulence factors of clinical strains ofCandida albicans
by essential oil of Cinnamomum zeylanicum. PSM Microbiol 3:4–
12
Chowdhary A, Voss A, Meis J (2016)Multidrug-resistantCandida auris:
‘new kid on the block’in hospital-associated infections? J Hosp
Infect 94:209–212. https://doi.org/10.1016/j.jhin.2016.08.004
Doyle AA, Stephens JC (2019) A review of cinnamaldehyde and its
derivatives as antibacterial agents. Fitoterapia 11:104405. https://
doi.org/10.1016/j.fitote.2019.104405
Elcocks E, Spencer-Phillips P, Adukwu E (2020) Rapid bactericidal ef-
fect of cinnamon bark essential oil against Pseudomonas
aeruginosa. J Appl Microbiol 128:1025–1037. https://doi.org/10.
1111/jam.14538
Espinel-Ingroff A, Chaturvedi V, Fothergill A, Rinaldi M (2002) Optimal
testing conditions for determining MICs and minimum fungicidal
concentrations of new and established antifungal agents for uncom-
monmolds: NCCLS collaborative study. J Clin Microbiol 40:3776–
3781. https://doi.org/10.1128/JCM.40.10.3776-3781.2002
Favero D, Furlaneto-Maia L, França EJ, Góes HP, Furlaneto MC (2014)
Hemolytic factor production by clinical isolates of Candida species.
Curr Microbiol 68:161–166. https://doi.org/10.1007/s00284-013-
0459-6
Gautam N, Mantha AK, Mittal S (2014) Essential oils and their constit-
uents as anticancer agents: a mechanistic view. Biomed Res Int
2014. https://doi.org/10.1155/2014/154106
Gow NA, Brown AJ, Odds FC (2002) Fungal morphogenesis and host
invasion. Curr Opin Microbiol 5:366–371. https://doi.org/10.1016/
S1369-5274(02)00338-7
Gruenwald J, Freder J, Armbruester N (2010) Cinnamon and health. Crit
Rev Food Sci Nutr 50:822–834. https://doi.org/10.1080/
10408390902773052
He M, Du M, Fan M, Bian Z (2007) In vitro activity of eugenol against
Candida albicans biofilms. Mycopathologia 163:137–143. https://
doi.org/10.1007/s11046-007-0097-2
KhanMSA, Ahmad I (2011) Antifungal activity of essential oils and their
synergy with fluconazole against drug-resistant strains of
Aspergillus fumigatus and Trichophyton rubrum. Appl Microbiol
Biotechnol 90:1083–1094. https://doi.org/10.1007/s00253-011-
3152-3
Khan MSA, Ahmad I (2013) In vitro inhibition of growth and virulence
factors production in azole-resistant strains of non-albicansCandida
by Cinnamomum verum, Cymbopogon citratus, Cymbopogon
martini and Syzygium aromaticum essential oils. J Biol Act Prod
Nat 3:139–153. https://doi.org/10.1080/22311866.2013.817729
8923Appl Microbiol Biotechnol (2020) 104:8911–8924
Khan MSA, Ahmad I, Cameotra SS (2013) Phenyl aldehyde and
propanoids exert multiple sites of action towards cell membrane
and cell wall targeting ergosterol in Candida albicans. AMB
Express 3:54. https://doi.org/10.1186/2191-0855-3-54
Knobloch K, Pauli A, Iberl B, Weigand H, Weis N (1989) Antibacterial
and antifungal properties of essential oil components. J Essent Oil
Res 1:119–128. https://doi.org/10.1080/10412905.1989.9697767
Larkin E, Hager C, Chandra J, Mukherjee PK, RetuertoM, Salem I, Long
L, Isham N, Kovanda L, Borroto-Esoda K, Wring S (2017) The
emerging pathogen Candida auris: growth phenotype, virulence
factors, activity of antifungals, and effect of SCY-078, a novel glu-
can synthesis inhibitor, on growth morphology and biofilm forma-
tion. Antimicrob Agents Chemother 6:e02396–e02416. https://doi.
org/10.1128/AAC.02396-16
Leite MCA, Bezerra APDB, Sousa JPD, Guerra FQS, Lima EDO (2014)
Evaluation of antifungal activity and mechanism of action of citral
against Candida albicans. Evid-Based Complementary Altern Med
2014. https://doi.org/10.1155/2014/378280
Li WR, Shi QS, Liang Q, Huang XM, Chen YB (2014) Antifungal effect
and mechanism of garlic oil on Penicillium funiculosum. Appl
Microbiol Biotechnol 98:8337–8346. https://doi.org/10.1007/
s00253-014-5919-9
Lo HJ, Köhler JR, DiDomenico B, Loebenberg D, Cacciapuoti A, Fink
GR (1997) Nonfilamentous C. albicans mutants are avirulent. Cell.
90:939–949. https://doi.org/10.1016/S0092-8674(00)80358-X
Lopes G, Pinto E, Andrade PB, Valentão P (2013) Antifungal activity of
phlorotannins against dermatophytes and yeasts: approaches to the
mechanism of action and influence on Candida albicans virulence
factor. PLoS One 8:e72203. https://doi.org/10.1371/journal.pone.
0072203
Luo G, Samaranayake LP, Yau JY (2001) Candida species exhibit dif-
ferential in vitro hemolytic activities. J Clin Microbiol 39:2971–
2974. https://doi.org/10.1128/JCM.39.8.2971-2974.2001
Malcok HK, Aktas E, Ayyildiz A, Yigit N, Yazgi H (2009) Hemolytic
activities of the Candida species in liquid medium. Eurasian J Med
41(2):95–98
Manns JM, Mosser DM, Buckley HR (1994) Production of a hemolytic
factor by Candida albicans. Infect Immun 62:5154–5156
Mayaud L, Carricajo A, Zhiri A, Aubert G (2008) Comparison of bacte-
riostatic and bactericidal activity of 13 essential oils against strains
with varying sensitivity to antibiotics. Lett Appl Microbiol 47:167–
173. https://doi.org/10.1111/j.1472-765X.2008.02406.x
Nayak AP, Green BJ, Beezhold DH (2013) Fungal hemolysins. Med
Mycol 51:1–16. https://doi.org/10.3109/13693786.2012.698025
Prasad KN, Yang B, Dong X, Jiang G, Zhang H, Xie H, Jiang Y (2009)
Flavonoid contents and antioxidant activities from Cinnamomum
species. Innov Food Sci Emerg Technol 10:627–632. https://doi.
org/10.1016/j.ifset.2009.05.009
Ranasinghe L, Jayawardena B, Abeywickrama K (2002) Fungicidal ac-
tivity of essential oils of Cinnamomum zeylanicum (L.) and
Syzygium aromaticum (L.) Merr et LM Perry against crown rot
and anthracnose pathogens isolated from banana. Lett Appl
Microbiol 35:208–211. https://doi.org/10.1046/j.1472-765X.2002.
01165.x
Raut JS, Karuppayil SM (2014) A status review on the medicinal prop-
erties of essential oils. Ind Crop Prod 62:250–264. https://doi.org/
10.1016/j.indcrop.2014.05.055
Sanla-Ead N, Jangchud A, Chonhenchob V, Suppakul P (2012)
Antimicrobial activity of cinnamaldehyde and eugenol and their
activity after incorporation into cellulose-based packaging films.
Packag Technol Sci 25:7–17. https://doi.org/10.1002/pts.952
Sardi JCO, Silva DR, Mendes-Giannini MJS, Rosalen PL (2018)
Candida auris: epidemiology, risk factors, virulence, resistance,
and therapeutic options. Microb Pathog 125:116–121. https://doi.
org/10.1016/j.micpath.2018.09.014
Sardi JCO, Scorzoni L, Bernardi T, Fusco-Almeida A, Giannini MM
(2013) Candida species: current epidemiology, pathogenicity, bio-
film formation, natural antifungal products and new therapeutic op-
tions. J Med Microbiol 62:10–24. https://doi.org/10.1099/jmm.0.
045054-0
Sears D, Schwartz BS (2017) Candida auris: an emerging multidrug-
resistant pathogen. International J Infect Dis 63:95–98. https://doi.
org/10.1016/j.ijid.2017.08.017
Shahina Z, El-GaninyAM,Minion J,WhitewayM, Sultana T, Dahms TE
(2018) Cinnamomum zeylanicum bark essential oil induces cell wall
remodelling and spindle defects in Candida albicans. Fungal Biol
Biotechnol 5:1–16. https://doi.org/10.1186/s40694-018-0046-5
Thompson DS, Carlisle PL, Kadosh D (2011) Coevolution of morphol-
ogy and virulence inCandida species. Eukaryot Cell 10:1173–1182.
https://doi.org/10.1128/EC.05085-11
Thosar N, Basak S, Bahadure RN, Rajurkar M (2013) Antimicrobial
efficacy of five essential oils against oral pathogens: an in vitro
study. Eur J Dent 7(Suppl 1):S71. https://doi.org/1305-
7456.119078/1305-7456.119078
Topa SH, Subramoni S, Palombo EA, Kingshott P, Rice SA, Blackall LL
(2018) Cinnamaldehyde disrupts biofilm formation and swarming
motility of Pseudomonas aeruginosa. Microbiol. 164:1087–1097.
https://doi.org/10.1099/mic.0.000692
Tworkoski T (2002) Herbicide effects of essential oils. Weed Sci 50:425–
431. https://doi.org/10.1614/0043-1745(2002)050[0425:HEOEO]
2.0.CO;2
Vaseeharan B, Thaya R (2014) Medicinal plant derivatives as
immunostimulants: an alternative to chemotherapeutics and antibi-
otics in aquaculture. Aquac Int 22:1079–1091. https://doi.org/10.
1007/s10499-013-9729-3
Velluti A, Sanchis V, Ramos A, Egido J, Marın S (2003) Inhibitory effect
of cinnamon, clove, lemongrass, oregano and palmarose essential
oils on growth and fumonisin B1 production by Fusarium
proliferatum in maize grain. Int J Food Microbiol 89:145–154.
https://doi.org/10.1016/S0168-1605(03)00116-8
Velluti A, Sanchis V, Ramos A, Turon C, Marin S (2004) Impact of
essential oils on growth rate, zearalenone and deoxynivalenol pro-
duction by Fusarium graminearum under different temperature and
water activity conditions in maize grain. J Appl Microbiol 96:716–
724. https://doi.org/10.1111/j.1365-2672.2004.02212.x
Wan L, Luo G, Lu H, Xuan D, Cao H, Zhang J (2015) Changes in the
hemolytic activity of Candida species by common electrolytes.
BMC Microbiol 15:171. https://doi.org/10.1186/s12866-015-0504-
7
Yunes RA, Cechinel Filho V, Ferreira J, Calixto JB (2005) The use of
natural products as sources of new analgesic drugs. Stud Nat Prod
Chem 30:191–212. https://doi.org/10.1016/S1572-5995(05)80033-
X
Zeng H, Chen X, Liang J (2015) In vitro antifungal activity and mecha-
nism of essential oil from fennel (Foeniculum vulgare L.) on der-
matophyte species. J Med Microbiol 64:93–103. https://doi.org/10.
1099/jmm.0.077768-0
Publisher’s note Springer Nature remains neutral with regard to jurisdic-
tional claims in published maps and institutional affiliations.
8924 Appl Microbiol Biotechnol (2020) 104:8911–8924
